MHE Question of the Week: Should the Medicare Cap Be Extended?
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
One of the most important provisions of the Inflation Reduction Act caps the out-of-pocket prescription drug costs of Medicare Beneficiaries. A $3,250 cap went into effect this year and will be lowered to $2,000 next year. But the limit only applies to those with Part D Medicare coverage, the part of Medicare that covers prescription drugs. President Joe Biden proposed extending the cap to health insurance sold on the commercial market in his State of the Union speech last week. Proponents of such limits say they make high-priced medications affordable, improving access to drugs that can reduce illness and lengthen lives. Detractors say limits will make premiums more expensive and also have long-term negative effects on the development of drugs.
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
Please pick the statement that most closely resembles your view
Should the Medicare $2,000 per-year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
Differences in Defining “Clinically Meaningful” in Metastatic Breast Cancer Care
October 4th 2024Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute, explains the importance of the term “clinically meaningful” and shares some of the ways it can be defined.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis
October 4th 2024Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.
Read More
